42 cos banned over supply of substandard drugs

Jaipur:  The Rajasthan Medical Services Corporation (RMSC) Wednesday issued orders banning 42 pharma companies from supplying drugs as the samples were found to be substandard under the state govt’s free medicine scheme.

Companies whose products failed the quality tests will be prohibited from participating in tenders.

RMSC managing director Neha Giri said, “This is an important step towards ensuring the quality and timely supply of medicines. We have banned 32 firms for one year, eight firms for two years, and two firms for three years due to their products failing the tests.”

According to the corporation’s quality policy, every batch of supplied medicine undergoes quality testing in an approved lab, and only those that pass are distributed to hospitals. These drugs were initially found substandard in preliminary tests, and upon confirmation, actions were taken against the respective supplier companies.

Giri said that the management of purchase and supply of medicines in the chief minister free medicine scheme is being further strengthened. Along with this, special focus is also being laid on the quality of medicines. Besides, more drugs were found to be substandard.

Related Posts

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval…

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma said the United States Food and Drug Administration (USFDA) has completed an inspection at its Paithan manufacturing facility in Maharashtra, conducted between 13 April and 21 April 2026.…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Boehringer Ingelheim launches AI centre for pharma research in London

Boehringer Ingelheim launches AI centre for pharma research in London

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March